Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Subcutaneous peginterferon-α-2a (40kD) [Pegasys®] is an effective and reasonably well tolerated treatment for the management of patients with hepatitis B e antigen (HBeAg)-negative or -positive chronic hepatitis B. It was significantly more effective than lamivudine monotherapy at inducing sustained virological response and ALT normalisation in both HBeAg-negative and -positive patients. Notably, the addition of lamivudine to peginterferon-α-2a (40kD) conferred no additional benefit versus peginterferon-α-2a (40kD) monotherapy. Moreover, in HBeAg-positive patients significantly more peginterferon-α-2a (40kD) recipients experienced HBeAg seroconversion than lamivudine recipients. The position of peginterferon-α-2a (40kD) relative to other treatment options remains to be fully determined. In the meantime, this agent appears to be a valuable new option for the management of patients with HBeAg-negative or -positive chronic hepatitis B.
A biomathematical model has been developed to describe hepatitis B virus (HB V) kinetics. The viral kinetic profile of peginterferon-α-2a (40kD) monotherapy appears different to that of peginterferon-α-2a (40kD) plus lamivudine, with HBV viraemic decline biphasic in monotherapy recipients and generally triphasic in recipients of combination therapy. Compared with lamivudine, peginterferon-α-2a (40kD) appears to inhibit HBV replication to a lesser extent, but has a similar or greater impact on overall clearance of infected cells, which may contribute to increased virological response.
Serum levels of subcutaneous peginterferon-α-2a (40kD) are maintained throughout the once-weekly dose administration interval.
Subcutaneous peginterferon-α-2a (40kD) administered once weekly has been evaluated in the treatment of adult patients with HBeAg-negative and -positive chronic hepatitis B in randomised, well designed trials. Endpoints assessed 24 weeks after treatment cessation are reported.
In patients with HBeAg-negative chronic hepatitis B, peginterferon-α-2a (40kD) 180 μg/week for 48 weeks as monotherapy or in combination with lamivudine was significantly more effective than lamivudine monotherapy, in terms of virological response (defined as an HBV DNA level of <20 000 copies/ mL [43% and 44% vs 29%]) or ALT normalisation (59% and 60% vs 44%). Peginterferon-α-2a (40kD) for 48 weeks was similarly effective in patients with HBeAg-positive chronic hepatitis B; in the corresponding treatment groups, the virological response rates (defined as an HBV DNA level of <100 000 copies/mL) were 32% and 34% versus 22% and the ALT normalisation rates were 41% and 39% versus 28%. Furthermore, in HBeAg-positive patients, HBeAg seroconversion rates were 32% and 27% in recipients of peginterferon-α-2a (40kD) administered alone or in combination with lamivudine, and were significantly higher than those in lamivudine monotherapy recipients (19%). In addition, hepatitis B surface antigen (HBsAg) seroconversion (indicative of complete response) occurred in a small group of peginterferon-α-2a (40kD) recipients, but in no recipients of lamivudine monotherapy. Notably in both HBeAg-negative and — positive patients, response rates in peginterferon-α-2a (40kD) recipients were similar irrespective of whether this agent was given as monotherapy or in combination with lamivudine.
Significantly more HBeAg-positive peginterferon-α-2a (40kD) recipients achieved a combined response of HBV DNA suppression (defined as an HBV DNA level of <500 000 copies/mL, serum ALT normalisation and HBeAg loss), compared with recipients of conventional interferon-α-2a (24% vs 12%) in a 24-week phase II proof-of-concept trial. Peginterferon-α-2a (40kD) also proved effective in several difficult-to-treat patient subgroups, including patients with HBV genotype C and those with high HBV DNA and/or low ALT levels at baseline.
The detrimental impact of peginterferon-α-2a (40kD) monotherapy on healthrelated quality of life in patients with HBeAg-negative and -positive chronic hepatitis B appears to be less than that historically seen in patients with chronic hepatitis C.
Subcutaneous peginterferon-α-2a (40kD) is reasonably well tolerated in adult patients, with ≤7% of patients discontinuing therapy because of adverse events. Treatment-emergent adverse events and laboratory abnormalities are typical of those documented previously with interferons, and the addition of lamivudine does not alter the tolerability profile of peginterferon-α-2a (40kD).
In the two largest trials, the most commonly occurring treatment-emergent adverse events in peginterferon-α-2a (40kD) recipients were pyrexia, fatigue, myalgia, headache, decreased appetite, alopecia, arthralgia, diarrhoea and injection-site reactions. At least one adverse event was reported in 87–89% of peginterferon-α-2a (40kD) recipients, and the incidence was similar irrespective of whether peginterferon-α-2a (40kD) was given as monotherapy or in combination with lamivudine. Among lamivudine monotherapy recipients, 56% of HBeAg-positive patients experienced at least one adverse event. The corresponding value in the HBeAg-negative group was 48% and was statistically significant versus peginterferon-α-2a (40kD) groups for overall treatment effect. Serious adverse events occurred in a similar proportion of patients across treatment groups (2–7%).
Among patients with HBeAg-negative chronic hepatitis B, dose modification for adverse events was necessary in 7% of peginterferon-α-2a (40kD) monotherapy recipients and in 13% of combination therapy recipients. Dose modification for laboratory abnormalities occurred in a similar incidence in the corresponding treatment groups (37% and 36%) and were commonly due to ALT elevation (8% and 3%), neutropenia (17% and 25%) and thrombocytopenia (19% and 12%). Dose modification for adverse events or laboratory abnormalities was not necessary in any HBeAg-negative lamivudine monotherapy recipients.
Patients with chronic hepatitis B appeared to tolerate peginterferon-α-2a (40kD) better than patients with chronic hepatitis C, with a lower incidence of depression and a generally lower incidence of individual adverse events.
- 13–14 September, 2002: Geneva, Switzerland. Consensus statement (long version). J Hepatol 39: pp. S3-S25 CrossRef
- Lok, AS, McMahon, BJ (2001) Chronic hepatitis B. Hepatology 34: pp. 1225-41 CrossRef
- Delaney, WE, Bartholomeusz, A, Locarnini, SA (2002) Evolving therapies for the treatment of chronic hepatitis B virus infection. Expert Opin Investig Drugs 11: pp. 169-87 CrossRef
- Keeffe, EB, Dieterich, DT, Han, SH (2004) A treatment algorithm for the management of chronic hepatitis B virus infection in the United States. Clin Gastroenterol Hepatol 2: pp. 87-106 CrossRef
- Lok, AS, Heathcote, J, Hoofnagle, JH (2001) Management of hepatitis B: 2000-summary of a workshop. Gastroenterology 120: pp. 1828-53 CrossRef
- Funk, ML, Rosenberg, DM, Lok, AS (2002) World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants. J Viral Hepat 9: pp. 52-61 CrossRef
- Chin, R, Locarnini, S (2003) Treatment of chronic hepatitis B: current challenges and future directions. Rev Med Virol 13: pp. 255-72 CrossRef
- Hadziyannis, SJ, Vassilopoulos, D (2001) Hepatitis B e antigen-negative chronic hepatitis B. Hepatology 34: pp. 617-24 CrossRef
- Conjeevaram, HS, Lok, ASF (2003) Management of chronic hepatitis B. J Hepatol 38: pp. S90-103 CrossRef
- Lok, AS, McMahon, BJ (2004) Chronic hepatitis B: update of recommendations. Hepatology 39: pp. 857-61 CrossRef
- Roche. Pegasys approved in the European Union for the treatment of chronic hepatitis B [media release; online]. Available from URL: http://www.roche.com [Accessed 2005 Feb 25]
- Keating, GM, Curran, M (2003) Peginterferon-α-2a (40kD) plus ribavirin: a review of its use in the management of chronic hepatitis C. Drugs 63: pp. 701-30 CrossRef
- Perry, CM, Jarvis, B (2001) Peginterferon-alpha-2a (40kD): a review of its use in the management of chronic hepatitis C. Drugs 61: pp. 2263-88 CrossRef
- Roche. Pegasys® (peginterferon alfa-2a): complete product information [online]. Available from URL: http://www.rocheusa.com [Accessed 2004 Nov 1]
- Sy S, Martin NE, Patel IH, et al. Drug interactions between PEG(40K)-IFNα-2a (PEGASYS™) and cytochrome P450 (CYP450)-metabolized drugs are unlikely except for those metabolized by CYP1A2 [abstract no. 52.009]. 9th International Congress on Infectious Diseases; 2000 Apr 10–13; Buenos Aires
- Colombatto, P, Bizzarri, R, Civitano, L (2004) HBV-DNA and infected hepatocytes dynamics in HBeAg-negative chronic hepatitis B patients treated with peginterferon alfa-2a (40kD) (Pegasys®), lamivudine, or Pegasys® plus lamivudine combination therapy using a new bio-mathematical model [abstract no. 1156 plus poster]. Hepatology 40: pp. 666A
- Martin NE, Sy SS, Modi M. The enhanced efficacy of PEG(40K)-IFNa-2a (PEGASYS™) in chronic hepatitis C (CHC) may be explained by the optimization of the pharmacokinetics (PK) of interferon (IFN) by a branched methoxy 40 kDa polyethylene glycol (PEG) moiety [abstract no.54.010]. 9th International Congress on Infectious Diseases; 2000 Apr 10–13; Buenos Aires
- Modi, MW, Fried, M, Reindollar, RW (2000) The pharmacokinetic behavior of pegylated (40KDA) interferon alfa-2a (Pegasys™) in chronic hepatitis C patients after multiple dosing [abstract no. 939]. Hepatology 32: pp. 394A CrossRef
- Marcellin, P, Lau, GKK, Bonino, F (2004) Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 351: pp. 1206-17 CrossRef
- European Agency for the Evaluation of Medicinal Products. Summary of product characteristics: Pegasys [online]. Available from URL: http://www.emea.eu.int [Accessed 2004 Nov 2]
- Sulkowski, M, Wright, T, Rossi, S (2005) Peginterferon alfa-2a does not alter the pharmacokinetics of methadone in patients with chronic hepatitis C undergoing methadone maintenance therapy. Clin Pharmacol Ther 77: pp. 214-24 CrossRef
- Cooksley, WG, Piratvisuth, T, Lee, SD (2003) Peginterferon α-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat 10: pp. 298-305 CrossRef
- Lau, G, Piratvisuth, T, Luo, KX (2004) Peginterferon alfa-2a (40KD) (PEGASYS®) monotherapy and in combination with lamivudine is more effective than lamivudine monotherapy in HBeAg-positive chronic hepatitis B: results from a large, multinational study [abstract no. 20 plus oral presentation]. Hepatology 40: pp. 171A
- Marcellin, P, Lau, G, Piratvisuth, T (2004) Better safety and quality of life in patients with chronic hepatitis B than in patients with chronic hepatitis C when treated with peginterferon alfa-2a (40KD) (PEGASYS®) monotherapy [abstract no. 1158 plus poster]. Hepatology 40: pp. 668A CrossRef
- Piratvisuth, T, Marcellin, P, Lau, G (2004) ALT flares and sustained ALT response in patients with HBeAg-negative chronic hepatitis B treated with peginterferon alfa-2a (40kD) (Pegasys®), peginterferon alfa-2a (40 kD) plus lamivudine or lamivudine alone [abstract no. 1137 plus poster]. Hepatology 40: pp. 656A-7A
- Perrillo, RP (2001) Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology 120: pp. 1009-22 CrossRef
- Germanidis, G, Lau, G, Marcellin, P (2004) Profound on-treatment viral suppression with peginterferon alfa-2a (40KD) (Pegasys®) plus lamivudine combination therapy limits the development of YMDD mutations, but does not improve sustained response rates over peginterferon alfa-2a (40KD) alone [abstract 1131 plus poster]. Hepatology 40: pp. 653A
- Cooksley, WGE, Lai, MY, Piratvisuth, T (2003) ALT flares in patients with HBeAg-positive chronic hepatitis B and treated with either conventional interferon alfa-2A or peginterferon alfa-2A (40KD) (PEGASYS®) are not necessary for a significant response to therapy [abstract no. 1180]. Hepatology 38: pp. 724
- Ware, JE (2000) SF-36 health survey update. Spine 25: pp. 3130-9 CrossRef
- Hassanein, T, Cooksley, G, Sulkowski, M (2004) The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C. J Hepatol 40: pp. 675-81 CrossRef
- Perrillo, RP (1993) Interferon in the management of chronic hepatitis B. Dig Dis Sci 38: pp. 577-93 CrossRef
- Regev, A, Schiff, ER (2001) Drug therapy for hepatitis B. Adv Intern Med 46: pp. 107-35
- Kleinman, A (2004) Culture and depression. N Engl J Med 351: pp. 951-3 CrossRef
- Roche Pharma (Switzerland) AG. Genehmigte Fachinformation. 2004 Dec 20. (Data on file)
- Roche. PEGASYS: Roche files chronic hepatitis B indication in the US, EU and Switzerland [media release; online]. Available from URL: http://www.roche.com [Accessed 2004 Jul 21]
- Dando, TM, Plosker, GL (2003) Adefovir dipivoxil: a review of its use in chronic hepatitis B. Drugs 63: pp. 2215-34 CrossRef
- Jarvis, B, Faulds, D (1999) Lamivudine: a review of its therapeutic potential in chronic hepatitis B [published erratum appears in Drugs 1999; 58 (4): 587]. Drugs 58: pp. 101-41 CrossRef
- Perrillo, RP (2004) Overview of treatment of hepatitis B: key approaches and clinical challenges. Semin Liver Dis 24: pp. 23-9 CrossRef
- Lok, AS, Lai, C-L, Leung, N (2003) Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 125: pp. 1714-22 CrossRef
- GlaxoSmithKline. Epivir-HBV (lamivudine) tablets prescribing information [online]. Available from URL: http://us.gsk.com/products/assets/us_epivir_hbv_pdf [Accessed 2005 Feb 9]
- Haria, M, Benfield, P (1995) Interferon-α-2a: a review of its pharmacological properties and therapeutic use in the management of viral hepatitis. Drugs 50: pp. 873-96 CrossRef
- Niederau, C, Heintges, T, Lange, S (1996) Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 334: pp. 1422-7 CrossRef
- Hadziyannis, SJ, Papatheodoridis, GV, Vassilopoulos, D (2003) Treatment of HBeAg-negative chronic hepatitis B. Semin Liver Dis 23: pp. 81-8 CrossRef
- Zonneveld, M, Honkoop, P, Hansen, BE (2004) Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology 39: pp. 804-10 CrossRef
- U. S. Food and Drug Administration. Drugs@FDA. Label and approval history [online]. Available from URL: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm [Accessed 2004 Dec 2]
- Gilead Sciences, Inc.. Hepsera (adefovir dipivoxil) tablets prescribing information [online]. Available from URL: http://www.gilead.com/pdf/hepsera_pi.pdf [Accessed 2005 Feb 9]
- Janssen, H, Zonneveld, M, Senturk, H (2005) Pegylated interferon alfa-2b alone or on combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 365: pp. 123-9 CrossRef
- Chan, H-Y, Leung, N-Y, Hui, AY (2005) A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-α2b and lamivudine with lamivudine alone. Ann Intern Med 142: pp. 240-50
- Bristol-Myers Squibb. Bristol-Myers Squibb submits applications in the U.S. and Europe to market entecavir, an investigational antiviral treatment for chronic hepatitis B infection [media release; online]. Available from URL: http://www.bms.com [Accessed 2004 Oct 24]
- Strader, D, Wright, T, Thomas, D (2004) Diagnosis, management, and the treatment of hepatitis C. Hepatology 39: pp. 1147-71 CrossRef
- Honkoop, P, Man, RA, Niesters, GM (2000) Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy. Hepatology 32: pp. 635-9 CrossRef
- Peginterferon-α-2a (40kD)
Volume 65, Issue 6 , pp 809-825
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Industry Sectors